Lineage Cell Therapeutics

LCTX · NYSE American

$0.9726+$0.0198 (+2.08%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.9528

Latest news

NewsOct 12, 7:43 AM ET
Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call
Press releaseSep 8, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Press releaseAug 6, 4:01 PM ETBusiness Wire
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 30, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Press releaseJul 13, 8:00 AM ETBusiness Wire
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Press releaseJul 6, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
NewsJul 1, 4:05 AM ET
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call
Press releaseMay 20, 9:50 AM ETPRNewswire
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Press releaseMay 12, 4:01 PM ETBusiness Wire
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
Press releaseMay 5, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
Press releaseMay 4, 8:00 AM ETBusiness Wire
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Press releaseApr 13, 8:00 AM ETBusiness Wire
Lineage Announces Formation of Scientific Advisory Board
Press releaseApr 10, 9:55 AM ETPRNewswire
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Press releaseMar 24, 8:00 AM ETBusiness Wire
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
NewsMar 18, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseMar 18, 10:00 AM ETPRNewswire
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
NewsMar 5, 4:04 PM ET
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways
NewsMar 5, 4:02 PM ET
Lineage Cell Therapeutics Q4 EPS $0.00 Beats $(0.05) Estimate, Sales $6.600M Beat $2.577M Estimate
Press releaseMar 5, 4:01 PM ETBusiness Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NewsMar 5, 6:11 AM ET
Earnings Scheduled For March 5, 2026
NewsMar 4, 1:01 PM ET
A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast
Press releaseFeb 26, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Press releaseJan 29, 1:31 PM ETPRNewswire
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Press releaseJan 6, 8:00 AM ETBusiness Wire
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
Press releaseJan 5, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics Issues Letter to Stockholders
Press releaseDec 16, 11:53 AM ETPRNewswire
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
NewsDec 4, 8:00 AM ETAvi Kapoor
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Press releaseNov 6, 4:01 PM ETBusiness Wire
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseOct 30, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Press releaseSep 8, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Press releaseSep 2, 8:00 AM ETBusiness Wire
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
NewsAug 27, 2:01 PM ET
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
Press releaseAug 26, 8:00 AM ETBusiness Wire
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
NewsAug 15, 1:07 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings Scheduled For May 12, 2026

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

12 Health Care Stocks Moving In Wednesday's After-Market Session

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways

Lineage Cell Therapeutics Q4 EPS $0.00 Beats $(0.05) Estimate, Sales $6.600M Beat $2.577M Estimate

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For March 5, 2026

A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Lineage Cell Therapeutics Issues Letter to Stockholders

Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 6, 2025

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

12 Health Care Stocks Moving In Friday's Intraday Session